More CYDY News:https://www.biocentury.com/article/
Post# of 153887
(Total Views: 612)
Posted On: 03/29/2020 1:17:25 PM
More CYDY News:https://www.biocentury.com/article/304761
EARLY DATA FOR CYTODYN MAB
CytoDyn Inc. (OTCQX:CYDY) reported results from the first four patients given leronlimab as part of an emergency IND. The biotech’s companion diagnostic showed that after three days of therapy, the immune profile in all four patients approached normal levels, with significant decreases in IL-6 and TNFa.
CytoDyn thinks its CCR5 antagonist could block pro-inflammatory cytokines and thus prevent cytokine storms associated with COVID-19 infection, helping patients recover from the pulmonary inflammation that drives mortality and the need for ventilators.
A total of seven patients have been enrolled in the Phase II trial thus far in a medical center in New York City. CytoDyn shares rose $0.43 (46%) to $1.37 Friday.
Further analysis of the coronavirus crisis can be found at BioCentury.
EARLY DATA FOR CYTODYN MAB
CytoDyn Inc. (OTCQX:CYDY) reported results from the first four patients given leronlimab as part of an emergency IND. The biotech’s companion diagnostic showed that after three days of therapy, the immune profile in all four patients approached normal levels, with significant decreases in IL-6 and TNFa.
CytoDyn thinks its CCR5 antagonist could block pro-inflammatory cytokines and thus prevent cytokine storms associated with COVID-19 infection, helping patients recover from the pulmonary inflammation that drives mortality and the need for ventilators.
A total of seven patients have been enrolled in the Phase II trial thus far in a medical center in New York City. CytoDyn shares rose $0.43 (46%) to $1.37 Friday.
Further analysis of the coronavirus crisis can be found at BioCentury.
(1)
(0)